Earnings summaries and quarterly performance for Vaxart.
Executive leadership at Vaxart.
Board of directors at Vaxart.
Research analysts who have asked questions during Vaxart earnings calls.
Mayank Mamtani
B. Riley Securities
6 questions for VXRT
Also covers: AGEN, ALT, ARWR +18 more
Liang Cheng
Jefferies
4 questions for VXRT
Also covers: AADI, CTMX, INO
Cheng Li
Oppenheimer & Co. Inc.
3 questions for VXRT
Also covers: EDIT, EXEL, INO +3 more
EK
Elaine Kim
H.C. Wainwright & Co.
1 question for VXRT
Also covers: ALDX
UA
Unknown Analyst
Morgan Stanley
1 question for VXRT
Also covers: ATEYY, BDORY, BSBR +19 more
Recent press releases and 8-K filings for VXRT.
Vaxart Reports Strong Q3 2025 Revenue and Secures Dynavax Partnership
VXRT
Earnings
M&A
Guidance Update
- Vaxart reported Q3 2025 revenue of $72.4 million, a substantial increase from $6.4 million in Q3 2024, primarily due to BARDA contracts.
- A strategic partnership with Dynavax for the oral COVID-19 vaccine candidate was announced, including an upfront license fee of $25 million and a $5 million equity investment. This agreement extends Vaxart's cash runway into the second quarter of 2027 and offers potential payments of up to $700 million in milestones and royalties.
- The COVID-19 phase 2b clinical study continues with BARDA funding for follow-up on approximately 5,400 enrolled subjects. 12-month top-line data from the Sentinel cohort is expected in Q1 2026, with data for all participants in Q4 2026.
- The norovirus program demonstrated positive Phase I data for its second-generation constructs, with the next clinical trial anticipated to begin in 2026 contingent on securing a partnership or other funding.
Nov 13, 2025, 9:30 PM
Vaxart Announces Q3 2025 Financial Results and Dynavax Licensing Agreement
VXRT
Earnings
New Projects/Investments
- Vaxart, Inc. reported revenue of $72.4 million for the third quarter of 2025, primarily from government contracts, and a net loss of $8.1 million, or $0.04 per share.
- The company entered an exclusive license agreement with Dynavax for its COVID-19 oral pill vaccine candidate, receiving an upfront payment of $25 million and a $5 million equity investment, with potential future proceeds of up to $700 million plus royalties.
- Vaxart completed enrollment of approximately 5,400 participants in its COVID-19 Phase 2b trial, with topline data expected in late 2026 and data from a sentinel cohort anticipated in the first quarter of 2026.
- As of September 30, 2025, Vaxart held $28.8 million in cash, cash equivalents, and investments, which is anticipated to extend its cash runway into the second quarter of 2027.
Nov 13, 2025, 9:11 PM
Vaxart Enters Exclusive License Agreement with Dynavax for Oral COVID-19 Vaccine Program
VXRT
New Projects/Investments
Equity Issuance
- Vaxart, Inc. entered into an exclusive, worldwide license and collaboration agreement with Dynavax Technologies Corporation for its investigational oral COVID-19 vaccine candidate on November 4, 2025.
- Dynavax will provide Vaxart with a $25 million upfront license fee and a $5 million equity investment.
- Vaxart will retain full operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the Phase 2b clinical trial and the subsequent End of Phase 2 meeting with the FDA.
- Dynavax has the right, but not the obligation, to elect to assume responsibility for continued clinical development after receiving the Phase 2b data, which would trigger an additional $50 million payment to Vaxart.
- If Dynavax assumes responsibility, Vaxart may also receive up to $195 million in regulatory milestone payments, up to $425 million in net sales milestone payments, and tiered royalties in the low-to-mid teens on potential future net sales.
Nov 5, 2025, 9:30 PM
Nasdaq Grants Vaxart Extension for Bid Price Rule Compliance
VXRT
Delisting/Listing Issues
Proxy Vote Outcomes
- Vaxart, Inc. received a decision letter from the Nasdaq Hearings Panel on August 27, 2025, granting its request for an extension to regain compliance with the Nasdaq minimum bid price requirement.
- The extension is subject to several conditions, including obtaining stockholder approval for a reverse stock split (RSS) by September 5, 2025, completing the RSS by October 6, 2025, and demonstrating compliance with the Bid Price Rule by October 17, 2025.
- Failure to obtain stockholder approval for the RSS by the September 5, 2025, deadline will result in the delisting of the company's securities.
Aug 29, 2025, 8:44 PM
Quarterly earnings call transcripts for Vaxart.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more